University of Alabama Comprehensive Cancer Center University of Alabama (8)
Welcome,         Profile    Billing    Logout  
 3 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Borate, Uma
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCI-2021-08484, NCT05379166: Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Recruiting
2
53
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Uma Borate
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
12/24
12/24
NCT05030441: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1

Recruiting
2
20
US
Ivosidenib, TIBSOVO
Washington University School of Medicine, Servier Hellas Pharmaceuticals Ltd., Gateway for Cancer Research
Clonal Cytopenia of Undetermined Significance
01/30
01/30
NCT05641831: Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Recruiting
2
110
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, ACZ885, Ilaris, Chest Radiography, Chest X-ray, Echocardiography, EC, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment
Uma Borate
Clonal Cytopenia of Undetermined Significance
12/25
12/28
NCI-2019-03712, NCT03878199: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Recruiting
1/2
47
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424
Ohio State University Comprehensive Cancer Center, Incyte Corporation, Jazz Pharmaceuticals
Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
12/24
12/24
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
NCT06523556: Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Recruiting
1/2
52
US
Axatilimab, Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352, Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
Uma Borate, Incyte Corporation
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
12/25
12/26
NCI-2019-01726, NCT03900949: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Active, not recruiting
1
18
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Midostaurin, CGP 41251, CGP41251, N-Benzoyl-Staurosporine, N-Benzoylstaurosporine, PKC-412, PKC412, Rydapt
Uma Borate
Acute Myeloid Leukemia
06/25
12/25
NCT06222580: SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, ASP-2215, ASP2215, Revumenib, Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613, Menin-MLL Inhibitor SNDX-5613, Menin-MLL Interaction Inhibitor SNDX-5613, SNDX 5613, SNDX-5613, SNDX5613
Uma Borate
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/25
12/25
NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated
1
33
Europe, US, RoW
MBG453, sabatolimab, NIS793, canakinumab, ACZ885
Novartis Pharmaceuticals
Myelodysplastic Syndromes
04/24
04/24
NCT06343805: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Recruiting
1
76
US
AJ1-11095
Ajax Therapeutics, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, PMF, PPV-MF, PET-MF
10/26
02/27
NCT05102370: A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Active, not recruiting
1
4
US
Enasidenib
Memorial Sloan Kettering Cancer Center
Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
10/25
10/25

Download Options